USCOM LIMITED — Regulatory Filings 2014

May 18, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Uscom appoints three new UK distributors for BP+ blood pressure monitor

Monday 19th of May 2014: Uscom (ASX code: UCM)

Uscom Limited is pleased to announce the appointment of three new specialist distributors of the Uscom BP+ suprasystolic oscillometric blood pressure monitor in the UK. MediMax Global and Healthwatchers have been appointed in England, and Castleblack Health in Ireland.

MediMax Global UK Ltd., established in 2007 is an approved accredited supplier to the NHS and NHS Supply Chain in the UK. The business is focused on diagnostic devices and consumables for the detection of cardiovascular and peripheral vascular disease in both primary and secondary care markets and in preventative cardiovascular care. Healthwatchers is a small distributor with expanding programmes in the UK home care and preventative health care markets. Castleblack Health Ltd is a medical device sales company based in Ireland that will promote the Uscom BP+ to the General Practitioner and Cardiology market in Ireland. The BP+ received the CE Mark in February 2014, allowing the Uscom BP+ device to be sold into the European Economic Area.

Executive Chairman of Uscom, Rob Phillips said, “The appointment of these three specialist distributors in the UK will shift our profile and deliver our technology into the hands of new users. Each of these distributors is specialized in the GP and home care clinical markets of hypertension and vascular health, and each have a commitment to disruptive technologies and excellent science. The Uscom BP+ suprasystolic blood pressure monitor suits their sales models perfectly. We are currently preparing to manufacture the Uscom BP+ and these distributors are a vital link in a new network of global BP+ distribution planned to come online in the next 12 months as manufacture increases to meet growing distributor demand.”

The BP+ device uses patent protected “suprasystolic oscillometry” to measure simply and noninvasively central blood pressure at the heart - measurements previously only available with invasive catheters, while older methods measure the pressure in the arm or hand. The unique BP+ measurements provide sensitive information about the health of the heart and vessels that are used to improve management of hypertension. These measurements are an improvement on conventional blood pressure measurements and can be applied in all research and clinical environments. Hypertension affects approximately 25% of all adults worldwide, and the hypertension market is thought to be in excess of $15billion US.

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat cardiovascular diseases, including hypertension and heart failure. The two products are also integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

References:

McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/eurojeartj/eht565� Avolio A. Central aortic blood pressure and management of hypertension: confirmation of a paradigm shift? Hypertension Editorial 2013; Sept 23

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au